| Bioactivity | Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy[1][2][3]. |
| Target | soluble activin receptor 2, ACVR2 |
| In Vivo | Ramatercept (10 mg/kg；皮下注射；每周 3 次，持续 5 周) 显著增加了小鼠的肌肉量[1]。 |
| Name | Ramatercept |
| CAS | 1169766-01-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fariello R G, et al. A novel Biological (FOX-115) improves endurance of motor performances in old mice (P2. 4-033)[J]. 2019. [2]. Feike Y, et al. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton). 2021 Aug 9;4(3):221-233. [3]. Louvel É. Dopage: nouveaux médicaments influant sur la biogenèse musculaire et mitochondriale[J]. 2019. |